[Federal Register Volume 86, Number 113 (Tuesday, June 15, 2021)]
[Notices]
[Page 31724]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-12451]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; Investigator Initiated Extended 
Clinical Trial (R01); NIAID Clinical Trial Planning Grant (R34); 
NIAID Clinical Trial Implementation Cooperative Agreement (U01); 
NIAID SBIR Phase II Clinical Trial Implementation Cooperative 
Agreement (U44).
    Date: June 28, 2021.
    Time: 12:30 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3F58, 
Rockville, MD 20892 (Virtual Meeting).
    Contact Person: Mario Cerritelli, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3F58, 
Rockville, MD 20852, 240-669-5199, [email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.
    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; Investigator Initiated Extended 
Clinical Trial (R01); NIAID Clinical Trial Planning Grant (R34); 
NIAID Clinical Trial Implementation Cooperative Agreement (U01); 
NIAID SBIR Phase II Clinical Trial Implementation Cooperative 
Agreement (U44).
    Date: June 29, 2021.
    Time: 11:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3F58, 
Rockville, MD 20892 (Virtual Meeting).
    Contact Person: Mario Cerritelli, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3F58, 
Rockville, MD 20852, 240-669-5199, [email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: June 9, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-12451 Filed 6-14-21; 8:45 am]
BILLING CODE 4140-01-P